| | | |

Multidisciplinary Care for Mesothelioma

multidisciplinary care for mesothelioma

Italian doctors say patients are more likely to enter clinical trials when they have multidisciplinary care for mesothelioma. 

Inclusion in clinical trials is one of the best ways for mesothelioma patients to access cutting edge treatments. 

The study shows multidisciplinary care for mesothelioma helps funnel patients into trials. It  also provides better monitoring of treatment response and better access to palliative care. 

What is the Multidisciplinary Approach?

In most hospitals, mesothelioma patients receive diagnosis from a cancer doctor or oncologist. The oncologist orders the appropriate diagnostic tests and helps craft the treatment plan. Diagnostic imaging or radiotherapy for mesothelioma is usually overseen by radiology specialists.

But multidisciplinary care for mesothelioma involves a bigger team of people. The team consists of providers from different disciplines. A multidisciplinary team typically includes oncologists and radiologists. But it may also include specialists such as: 

  • oncology nurses 
  • case managers 
  • pathologists 
  • radiation oncologists 
  • pharmacists 
  • palliative medicine doctors, and others 

Multidisciplinary care for mesothelioma provides well-rounded care for the whole person. It is the standard of care for several other cancers. 

Assessing Multidisciplinary Care for Mesothelioma

Humanitas Gavazzeni Hospital in Bergamo, Italy instituted multidisciplinary care for mesothelioma in January 2017. The team includes 

  • 4 medical oncologists 
  • a palliative care physician
  • 2 radiologists 
  • a radiation oncologist
  • a thoracic surgeon 
  • a research nurse 
  • and two data managers 

A pharmacist, pathologist, and lab biologist help as needed. The team discusses multidisciplinary care for mesothelioma at diagnosis, during treatment, and in follow-up. The goal of the study was to see how the approach affected patient care. 

A total of 188 mesothelioma patients received referrals to the hospital between 2014 and October of 2017. Twenty-three of those patients were enrolled in 2017. 

“Since the starting of multidisciplinary team meetings, 7/23 (30%) cases were subsequently enrolled in a clinical trial, versus 35/165 (21%) in the 2014-2016 period,” writes lead author Letizia Gianoncelli. “The rate of patient inclusion in clinical trials is improved when a dedicated multidisciplinary team discusses all referred cases.”

Other Benefits of Multidisciplinary Care

Multidisciplinary care for mesothelioma also gave more patients access to palliative care. Palliative care helps manage mesothelioma symptoms like pain and shortness of breath. The team approach also resulted in more careful tracking of patients’ treatment response. 

The researchers conclude that multidisciplinary care for mesothelioma is “very effective at providing timely diagnostic and therapeutic recommendations.” 

Multidisciplinary care is more common at high-volume cancer centers.  The Italian researchers say this is where pleural mesothelioma patients will get the best outcomes. 

Source: 

Gianoncelli, L, et al, “Malignant pleural mesothelioma multidisciplinary team unit: experience of one high-volume center in Italy”, Annals of Oncology, Volume 28, Supplement 6, https://www.annalsofoncology.org/article/S0923-7534(20)34866-3/fulltext

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…